4-[5-(5-oxyfuro[3,2-c]pyridin-2-yl)-[1.2.4]oxadiazol-3-ylmethyl]piperidine-1-carboxylic acid tert-butyl ester | 895125-72-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[5-(5-oxyfuro[3,2-c]pyridin-2-yl)-[1.2.4]oxadiazol-3-ylmethyl]piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 4-[[5-(5-oxidofuro[3,2-c]pyridin-5-ium-2-yl)-1,2,4-oxadiazol-3-yl]methyl]piperidine-1-carboxylate
• CAS: 895125-72-1
• 化学式: C₂₀H₂₄N₄O₅
• 分子量: 400.434
• InChiKey: REDXZFIWPALNKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  107
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-[5-(5-oxyfuro[3,2-c]pyridin-2-yl)-[1.2.4]oxadiazol-3-ylmethyl]piperidine-1-carboxylic acid tert-butyl ester 、 三甲基氰硅烷 在 二甲氨基甲酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 生成 4-[5-(4-cyanofuro[3,2-c]pyridin-2-yl)-[1.2.4]oxadiazol-3-ylmethyl]-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  WO2006/67532

  摘要：

  公开号：
• 作为产物：
  描述：

  4-(5-furo[3,2-c]pyridin-2-yl-[1.2.4]oxadiazol-3-ylmethyl)piperidine-1-carboxylic acid tert-butyl ester 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 17.0h， 生成 4-[5-(5-oxyfuro[3,2-c]pyridin-2-yl)-[1.2.4]oxadiazol-3-ylmethyl]piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  WO2006/67532

  摘要：

  公开号：

文献信息

• G-Protein Coupled Receptor Agonists
  申请人：Fyfe Matthew Colin Thor

  公开号：US20090099227A1

  公开（公告）日：2009-04-16

  Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.

  化合物式（I）或其药学上可接受的盐或N-氧化物，是GPR116激动剂，可用于治疗肥胖症和糖尿病的治疗。
• Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP2253311A2

  公开（公告）日：2010-11-24

  The present invention relates to the use of GPR119 receptor agonists for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. The present invention further relates to the use of a GPR119 receptor agonist in combination with a dipeptidyl peptidase IV (DPP-IV) inhibitor for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. A GPR119 receptor agonist and the combination of a GPR119 receptor agonist and a DPP-IV inhibitor promote bone formation in an individual.

  本发明涉及 GPR119 受体激动剂用于治疗或预防以低骨量为特征的疾病，如骨质疏松症，以及用于增加个体的骨量。本发明进一步涉及 GPR119 受体激动剂与二肽基肽酶 IV (DPP-IV) 抑制剂联合用于治疗或预防以低骨量为特征的疾病，如骨质疏松症，以及增加个体的骨量。GPR119 受体激动剂以及 GPR119 受体激动剂与 DPP-IV 抑制剂的组合可促进个体的骨形成。
• G-PROTEIN COUPLED RECEPTOR AGONISTS
  申请人：Prosidion Limited

  公开号：EP1838706A1

  公开（公告）日：2007-10-03
• USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO
  申请人：Arena Pharmaceuticals, Inc.

  公开号：EP2004157B1

  公开（公告）日：2011-01-12
• GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto
  申请人：Chu Zhi-Liang

  公开号：US20090270422A1

  公开（公告）日：2009-10-29

  The present invention relates to the use of GPR119 receptor agonists for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. The present invention further relates to the use of a GPR119 receptor agonist in combination with a dipeptidyl peptidase IV (DPP-IV) inhibitor for treating or preventing a condition characterized by low bone mass, such as osteoporosis, and for increasing bone mass in an individual. A GPR119 receptor agonist and the combination of a GPR119 receptor agonist and a DPP-IV inhibitor promote bone formation in an individual.